{"id":909224,"date":"2025-11-12T17:23:03","date_gmt":"2025-11-12T22:23:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/korro-reports-third-quarter-financial-results-provides-updates-on-krro-110-in-alpha-1-antitrypsin-deficiency-and-additional-pipeline-programs\/"},"modified":"2025-11-12T17:23:03","modified_gmt":"2025-11-12T22:23:03","slug":"korro-reports-third-quarter-financial-results-provides-updates-on-krro-110-in-alpha-1-antitrypsin-deficiency-and-additional-pipeline-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/korro-reports-third-quarter-financial-results-provides-updates-on-krro-110-in-alpha-1-antitrypsin-deficiency-and-additional-pipeline-programs\/","title":{"rendered":"Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — <\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\u2014<\/td>\n\n KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u2014<\/td>\n\n KRRO-110 did not reach projected levels of functional protein following a single administration\u00a0 <\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u2014<\/td>\n\n Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u2014<\/td>\n\n Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u2014<\/td>\n\n Reports third quarter 2025 financial results; ended third quarter 2025 with $102.5 million in cash, cash equivalents and marketable securities; extending cash runway into second half of 2027 by implementing a strategic restructuring<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

CAMBRIDGE, Mass., November 12, 2025 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today provided a program update for its Phase 1\/2a REWRITE clinical trial of KRRO-110 in AATD, reported financial results for the third quarter of 2025, and provided a business update.<\/p>\n

\u201cToday, we announced that KRRO-110 generated functional M-AAT protein in AATD patients. We\u2019re encouraged by the evidence of clinical activity, which we believe confirms our ability to edit RNA and produce therapeutic proteins in humans. While a single administration of KRRO-110 achieved functional protein production, it did not achieve the protein levels we projected based on preclinical data. Initial analysis indicates differences in the pharmacokinetics of the delivery components observed between healthy volunteers and AATD patients. The valuable insights gained from REWRITE, combined with the significant progress we\u2019ve made in potency, have informed our strategic decision to advance a GalNAc-conjugated construct for AATD. We are on track for a potential development candidate nomination in the first half of 2026.\u201d said Ram Aiyar, Ph.D., CEO and President of Korro Bio.<\/p>\n

\u201cIn addition, we have nominated our next development candidate, KRRO-121, a GalNAc-conjugated construct that activates a biological pathway by creating a de novo variant, for patients with hyperammonemia. This marks our first step in expanding our proprietary RNA editing platform beyond protein repair. We are working to advance KRRO-121 and a GalNAc version for AATD patients into the clinic in the second half of 2026 and in 2027, respectively.\u201d<\/p>\n

\u201cTo focus our resources on generating clinical data and advancing additional GalNAc-conjugated programs targeting the liver, we are implementing a strategic restructuring that reduces our workforce by approximately a third while extending our cash runway into the second half of 2027. We are grateful for our employees and their commitment. A special thanks to the AATD community, the participants in the REWRITE study, and the investigators who are continuing to work with us as we evaluate next steps for the program. We remain committed to our mission of delivering transformative genetic medicines to patients.\u201d<\/p>\n

\n
\n REWRITE Clinical Trial Update<\/u>
\n <\/strong>:<\/p>\n

The REWRITE Phase 1\/2a clinical trial is a two-part single and multiple-dose escalating study evaluating the safety and tolerability of KRRO-110, including healthy adults and clinically stable AATD patients with the PiZZ genotype. Korro has completed all six planned single ascending dose (SAD) healthy volunteer (HV) cohorts. Each HV cohort consisted of six participants, with four receiving active drug and two receiving placebo. Doses of KRRO-110 tested in the HVs (n=24) include 0.04, 0.1, 0.2, 0.4, 0.8 and 1.2 mg\/kg, with the primary objective to evaluate safety and tolerability. KRRO-110 is currently being evaluated in two AATD patient cohorts at 0.6 mg\/kg (n=3) and 0.8 mg\/kg (n=4), with seven patients dosed. The AATD patient cohorts are open label with up to four patients in each cohort. There are currently no plans to complete additional SAD patient cohorts for KRRO-110. Korro is evaluating the totality of the clinical data to evaluate the next steps, if any, for KRRO-110 in the multiple-ascending dose (MAD) portion of the REWRITE clinical trial.<\/p>\n

\n
\n Key Findings Include<\/u>
\n <\/strong>:<\/p>\n

\n KRRO-110 Safety Observations (as of the November 6, 2025 Data Cutoff Date):<\/em>\n <\/p>\n